Anne Li April 2nd, 2017
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices, according to a new study. Neoadjuvant chemoradiation is established practice for esophageal adenocarcinoma patients with locally advanced and/or node-positive tumors. The challenge for clinicians is to determine which esophageal cancer patients will derive benefit from neoadjuvant chemoradiation, which can lead to either a pathologic complete response or to persistent or even progressive disease. Up to 70% of patients will be downstaged as a result of neoadjuvant chemoradiation, stated the researchers, led by Emmanuel Gabriel, MD, PhD, of the department of surgical oncology at Roswell Park Cancer Institute in Buffalo, New York. However, some patients do not benefit and neoadjuvant chemoradiation may even result in higher mortality.
See original article at: http://www.cancernetwork.com/gastrointestinal-cancer/novel-calculator-guides-treatment-choice-esophageal-cancer